Yi-Hsien Cheng
Overview
Explore the profile of Yi-Hsien Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tannergren C, Arora S, Babiskin A, Borges L, Chatterjee P, Cheng Y, et al.
Mol Pharm
. 2024 Dec;
22(1):5-27.
PMID: 39680866
This report summarizes the proceedings for Day 3 of the workshop titled "". This day focused on the current and future drug product quality applications of PBBM from the innovator...
2.
Chen Q, Yuan L, Chou W, Cheng Y, He C, Monteiro-Riviere N, et al.
ACS Nano
. 2023 Oct;
17(20):19810-19831.
PMID: 37812732
Low tumor delivery efficiency is a critical barrier in cancer nanomedicine. This study reports an updated version of "Nano-Tumor Database", which increases the number of time-dependent concentration data sets for...
3.
Chou W, Tell L, Baynes R, Davis J, Cheng Y, Maunsell F, et al.
Food Chem Toxicol
. 2023 Sep;
181:114062.
PMID: 37769896
Humans can be exposed to per- and polyfluoroalkyl substances (PFAS) through dietary intake from milk and edible tissues from food animals. This study developed a physiologically based pharmacokinetic (PBPK) model...
4.
Chou W, Chen Q, Yuan L, Cheng Y, He C, Monteiro-Riviere N, et al.
J Control Release
. 2023 Jul;
361:53-63.
PMID: 37499908
The critical barrier for clinical translation of cancer nanomedicine stems from the inefficient delivery of nanoparticles (NPs) to target solid tumors. Rapid growth of computational power, new machine learning and...
5.
Lin Z, Aryal S, Cheng Y, Gesquiere A
ACS Nano
. 2022 Dec;
16(12):19722-19754.
PMID: 36520546
Nanomaterials (NMs) have been increasingly used in a number of areas, including consumer products and nanomedicine. Target tissue dosimetry is important in the evaluation of safety, efficacy, and potential toxicity...
6.
Chou W, Cheng Y, Riviere J, Monteiro-Riviere N, Kreyling W, Lin Z
Part Fibre Toxicol
. 2022 Jul;
19(1):47.
PMID: 35804418
Background: Physiologically based pharmacokinetic (PBPK) modeling is an important tool in predicting target organ dosimetry and risk assessment of nanoparticles (NPs). The methodology of building a multi-route PBPK model for...
7.
Lin Z, Chou W, Cheng Y, He C, Monteiro-Riviere N, Riviere J
Int J Nanomedicine
. 2022 Apr;
17:1365-1379.
PMID: 35360005
Background: Low delivery efficiency of nanoparticles (NPs) to the tumor is a critical barrier in the field of cancer nanomedicine. Strategies on how to improve NP tumor delivery efficiency remain...
8.
Cheng Y, He C, Riviere J, Monteiro-Riviere N, Lin Z
ACS Nano
. 2020 Feb;
14(3):3075-3095.
PMID: 32078303
Numerous studies have engineered nanoparticles with different physicochemical properties to enhance the delivery efficiency to solid tumors, yet the mean and median delivery efficiencies are only 1.48% and 0.70% of...
9.
DeLong R, Cheng Y, Pearson P, Lin Z, Coffee C, Mathew E, et al.
J Pharmacol Exp Ther
. 2019 May;
370(3):671-681.
PMID: 31040175
The unique anticancer, biochemical, and immunologic properties of nanomaterials are becoming a new tool in biomedical research. Their translation into the clinic promises a new wave of targeted therapies. One...
10.
Li M, Cheng Y, Chittenden J, Baynes R, Tell L, Davis J, et al.
Arch Toxicol
. 2019 Apr;
93(7):1865-1880.
PMID: 31025081
Violative chemical residues in animal-derived food products affect food safety globally and have impact on the trade of international agricultural products. The Food Animal Residue Avoidance Databank program has been...